Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1988 1
1989 1
1990 1
1991 1
1992 2
1993 5
1994 2
1995 6
1996 7
1997 9
1998 7
1999 14
2000 4
2001 3
2002 4
2003 3
2004 3
2005 5
2006 5
2007 1
2008 1
2010 2
2011 1
2012 3
2013 1
2014 1
2019 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 8917192

93 results

Results by year

Filters applied: . Clear all
Page 1
Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial.
Kraeber-Bodéré F, Bardet S, Hoefnagel CA, Vieira MR, Vuillez JP, Murat A, Ferreira TC, Bardiès M, Ferrer L, Resche I, Gautherot E, Rouvier E, Barbet J, Chatal JF. Kraeber-Bodéré F, et al. Clin Cancer Res. 1999 Oct;5(10 Suppl):3190s-3198s. Clin Cancer Res. 1999. PMID: 10541363 Clinical Trial.
Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I/II trial.
Vuillez JP, Kraeber-Bodéré F, Moro D, Bardiès M, Douillard JY, Gautherot E, Rouvier E, Barbet J, Garban F, Moreau P, Chatal JF. Vuillez JP, et al. Clin Cancer Res. 1999 Oct;5(10 Suppl):3259s-3267s. Clin Cancer Res. 1999. PMID: 10541373 Clinical Trial.
Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, Ferrer L, Faivre-Chauvet A, Campion L, Vuillez JP, Devillers A, Chang CH, Goldenberg DM, Chatal JF, Barbet J. Kraeber-Bodéré F, et al. J Nucl Med. 2006 Feb;47(2):247-55. J Nucl Med. 2006. PMID: 16455630 Free article. Clinical Trial.
Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections.
Kraeber-Bodéré F, Faivre-Chauvet A, Saï-Maurel C, Campion L, Fiche M, Gautherot E, Le Boterff J, Barbet J, Chatal JF, Thédrez P. Kraeber-Bodéré F, et al. Clin Cancer Res. 1999 Oct;5(10 Suppl):3183s-3189s. Clin Cancer Res. 1999. PMID: 10541362
93 results